The CKD market across the seven major markets (7MM) — the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan — stood at roughly USD 5 billion in 2025, with continued growth projected through 2036. This valuation reflects the current treatment landscape, which spans erythropoietin stimulating agents, ACE inhibitors, ARBs, antidiabetic drugs, secondary hyperparathyroidism therapies, and urate-lowering agents, alongside the fast-growing SGLT2 inhibitor and non-steroidal MRA classes that now anchor standard of care.
Chronic Kidney Disease Epidemiology
Understanding disease burden is central to forecasting the chronic kidney disease epidemiology forecast. In 2025, an estimated 82.5 million people across the 7MM were living with the condition, of whom nearly 14.5 million had been formally diagnosed. The US carried the largest diagnosed burden, accounting for about a quarter of the 7MM total, with roughly 3.8 million cases. Within the US population, Stage III disease was the most common severity level, and hyperparathyroidism emerged as the leading complication, ahead of anemia and metabolic acidosis. Diagnosed prevalence also skewed female, and the patient pool is expected to keep expanding as the geriatric population grows and screening through eGFR and albuminuria testing becomes more routine — trends that directly shape the broader kidney disease market over the coming decade.
Current Chronic Kidney Disease Treatment Landscape
Management typically follows a stepwise model: RAS blockade and lifestyle changes first, followed by SGLT2 inhibitors such as empagliflozin (JARDIANCE) and dapagliflozin (FARXIGA/FORXIGA) as a foundational layer across most disease etiologies. For patients with diabetes-related disease and persistent albuminuria, the non-steroidal MRA finerenone (KERENDIA) is increasingly layered on top to further reduce cardiorenal risk. This additive approach to therapy is the core reason the chronic kidney disease treatment market has shifted from single-agent RAS blockade toward multi-drug combination regimens.
Key Factors Driving the Chronic Kidney Disease Market
Three forces stand out. First, rising diagnosis rates driven by expanded screening in diabetic, hypertensive, and cardiovascular patient populations are pulling more people into treatment earlier. Second, the shift toward combination cardiorenal therapy — pairing SGLT2 inhibitors with non-steroidal MRAs and emerging aldosterone synthase inhibitors — is becoming the default rather than the exception, and is described as the primary revenue driver for the sector. Third, a diversifying late-stage pipeline, including endothelin receptor antagonism, aldosterone synthase inhibition, APOL1 inhibition, and cell-based therapy, is broadening the competitive field beyond the SGLT2 inhibitor/MRA backbone, pushing overall chronic kidney disease drugs market expansion.
Chronic Kidney Disease Drug Analysis & Competitive Landscape
Beyond the approved backbone therapies, several late-stage candidates are positioned to reshape competition. AstraZeneca’s zibotentan/dapagliflozin combination built on strong Phase IIb results before advancing into Phase III proteinuria studies. Boehringer Ingelheim’s vicadrostat plus empagliflozin combination has shown meaningful reductions in albuminuria in earlier-phase testing. ProKidney’s cell-therapy candidate rilparencel and Mineralys Therapeutics’ lorundrostat are also progressing through late-stage development, while Maze Therapeutics’ MZE829 recently produced the first clinical proof-of-concept data in APOL1-mediated kidney disease. Collectively, these programs illustrate how the chronic renal failure market is diversifying beyond its traditional glycemic- and blood-pressure-focused roots.
Chronic Kidney Disease Unmet Needs
Despite this progress, significant gaps remain. Current therapies slow rather than halt or reverse disease progression, and because early-stage disease is largely symptom-free, many patients are diagnosed only after substantial kidney damage has occurred. Even with combination SGLT2 inhibitor and MRA use, residual cardiorenal risk persists, and precision options remain scarce for genetically driven subtypes such as APOL1-mediated disease — gaps that continue to shape demand within the renal failure treatment market.
Chronic Kidney Disease Market Outlook
Looking ahead, SGLT2 inhibitors and finerenone are expected to remain the volume backbone of treatment, while endothelin- and aldosterone-pathway combinations drive the next wave of add-on growth, pending outcomes and safety data. Rilparencel and MZE829 could command premium positioning in advanced and genetically defined disease if trial results hold up, and anemia-focused candidates like DISC-0974 may open an additional revenue segment. Regionally, the US represents the largest share of the chronic kidney disease market size, followed by Germany and the UK among European markets, and Japan capturing a meaningful double-digit share of the 7MM total. Related segments, including therapies for advanced disease and the end stage renal disease market, are also expected to benefit as diagnosis rates climb and the late-stage pipeline matures through 2036.
Latest Reports Offered by Delveinsight
achromatopsia market | urinary catheters market | chronic wounds market | stem cell market | orthopedic power devices market | surgical stapling devices market | congenital myasthenic syndromes market | syncope market | addison’s disease market | bone growth stimulator market | contrast-induced nephropathy market | ependymoma market | mucinous cystic neoplasms market | poliomyelitis market | childhood atropine for myopia progression market | congenital diarrheal disorders market | erdheim-chester disease market | coronary stents pipeline | biliary tumor market | dilators market | vulvar cancer market | bladder scanners market | dementia with diabetes market | diabetic retinopathy market | erectile dysfunction market |
About Delveinsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk